This site is intended for healthcare professionals

First patient dosed in phase III XTEND-Kids study with efanesoctocog alfa in children with haemophilia A.- Swedish Orphan Biovitrum.

Read time: 1 mins
Last updated:14th Apr 2021
Published:14th Apr 2021
Condition: Haemophilia A
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest